The mid-year totals are a head-fake: underwrite the date, not the tour

Pollstar’s 2026 Mid-Year analysis leads with records — the Top 100 tours grossed $3.16B worldwide, up 12.3%, on 26.3M tickets, up 12.8% (Pollstar). Those are real, and they are the wrong number to book against.

The figure a Promoter Brief actually models is the per-show average, and it fell. Per-show gross dropped from $1.71M to $1.63M, down 5%, while tickets per show slid from 14,229 to 13,574, down 4.6% (Pollstar). The headline went up; the date got softer.

The records came from playing more shows, not selling more per show

The whole gap between those two stories is the denominator. The Top 100 grossed more because they played 18.2% more shows, not because each show drew more (Pollstar).

Run the arithmetic the other way and it closes cleanly. Tickets up 12.8% on a show count up 18.2% is fewer tickets per date — which is exactly the 4.6% per-show drop the report records. The aggregate rose because the schedule grew faster than the per-date softening fell.

The industry framed it honestly in Pollstar’s own words: “we’re putting on more shows for more fans and thankfully earning record-setting ticketing revenues” (Pollstar). More shows, more fans, record revenue — all true at the tour level, all silent on the date.

The per-show drop is a thinner room, not a discount

It would be easy to read a falling per-show gross as buyers holding out for a markdown. The data closes that door. Average ticket price barely moved — $120.43 to $119.92, down 0.4% — so the per-show gross fell because the rooms ran thinner, not cheaper (Pollstar).

That distinction is the whole point for a buyer. A price-led softening is a pricing problem you solve at the On-Sale Window — it’s the one we covered when buyers wait out the on-sale for the discount. A volume-led softening is a capacity problem you solve before the offer, by sizing the room to the date instead of the tour.

These are different failures with different fixes, and the 2026 first-half number is the second one. Fewer seats moved per night at a flat price.

North America is the same story, only sharper

If the worldwide figures feel abstract, North America makes the unit-of-analysis trap concrete. The region’s aggregate gross was flat at $1.923B, up 0.1% — and its per-show average gross fell 7.8% to $1,141,221 (Pollstar).

Read those two numbers next to each other. The same pool of money, spread across more dates, is less money per date — a per-show ticket average down 5.6%, steeper than the 4.6% worldwide (Pollstar).

A promoter reading “North American touring held its record pace” would be reading the aggregate. The date in front of them lost nearly eight points of gross.

Add three months to the same year and the split holds

Pollstar’s Q3 analysis covers November 13, 2025 through August 12, 2026 — the same reporting year as the mid-year print, with three more months on it (Pollstar). That makes it a harder test than a fresh data point: the same window, extended through the summer, and the per-show line still fell.

The totals got bigger. The Top 100 grossed $6.12B through three quarters, up 5.3% over 2025’s $5.81B and the first time Q3 revenues have topped $6B for the hundred highest-grossing artists; 47,453,010 tickets set a global Q3 attendance record, up 4.9% (Pollstar).

The per-show averages fell again — gross per show down 5.4%, tickets per show down 5.8% (Pollstar). At mid-year those same two lines were down 5% and 4.6%.

Run the arithmetic the other way and it closes again. Tickets up 4.9% while tickets per show fell 5.8% is roughly 11% more dates. Pollstar doesn’t publish a Q3 show count, but run that same calculation on the mid-year print and it returns 18.2% — the figure Pollstar states there.

The same mechanism shows up inside the top 10: 332 shows, 29 more than a year earlier, with gross up 9.8% and tickets up 5.1% on a show count up about 9.6% (Pollstar). Per-show gross was essentially flat; tickets per show fell about 4%.

At mid-year the per-show drop was volume rather than discounting, because price barely moved. At Q3 the decomposition is sharper. The average ticket price set a record at $129.07, up 0.5%, while tickets per show fell 5.8% — so the entire per-show gross decline is volume, and price added half a point on top of it at an all-time high (Pollstar). Multiply the two and you get 5.3% down, which closes on the 5.4% Pollstar reports. The room got thinner while the ticket got more expensive than it has ever been.

Pollstar calls the fall “more of a correction than a decline,” because 2025’s per-show gross average ran almost 30% above 2024’s on a greater number of stadium shows (Pollstar). Take the point, then notice it is the same mechanism: a correction off a stadium-heavy year is a mix-and-volume story.

The trade also scopes its own data. It “only represents the largest tours and not the mid-level and smaller tours” (Pollstar). The dataset that shows per-show softening stops above the rooms you buy.

Asked at a Goldman Sachs conference about the possibility of business slowing down in 2027, Live Nation president and CFO Joe Berchtold said: “We’ve seen nothing. And again, on a global basis, every week we get the numbers, U.S., U.K., Mexico, Latin America, we’re not seeing any real issue that would say that we’ve got any macro problem at all” (Pollstar). At the level he is describing, he is right — the totals are records. It is not the level a promoter books at, and that is the same reason the macro is the wrong number to price against.

A booking is a per-show bet

This is a different cut than the one we’ve run before. Reading the market by room size — the squeeze in the middle and the squeeze at the bottom — splits the Top tier from the small rooms. This isn’t a tier story. It’s the whole Top 100, where the total and the per-unit moved in opposite directions because the schedule grew underneath them.

The reason it matters to an independent promoter is structural. You are not booking a tour. You are booking one date in one market — a single per-show bet — and the per-show average is the population your bet lives in.

Benchmark an offer to an act’s record-setting tour total and you have anchored to the number that grew. The number you actually have to clear is the one that fell — and it is falling into a rising cost base that thins the margin from the other side.

Underwrite the date, not the tour

The correction is not to distrust the touring data. It’s to use the part of it that describes your actual exposure. Anchor the offer to the date’s own Comparable Shows and a capacity sized to this market — the per-date outputs — not to the tour’s headline gross (Pollstar).

That is the entire job of a Promoter Brief: a market fit grade, a recommended capacity, tiered pricing, and a revenue range — all scoped to one date, because the booking is one date. The macro per-show softening is the case for that scope, not against it. When per-show averages slip while routing expands, the tour total is the least reliable proxy for what a single night will do.

The date carries more than economics. The risks that decide an outdoor show — a competing on-sale, a Radius Clause, and now the heat itself — land on the specific date, not the tour, and they price the same way. On a hot summer date that means underwriting the heat, not the season.

Frame any specific number as a range, not a promise. Match the unit of the data to the unit of the bet.

The one for Monday

Before you size a guarantee off a “record year” touring headline, find the per-show line underneath it. In Pollstar’s 2026 first half it was down 5% worldwide and 7.8% in North America, even as the totals set records (Pollstar). Three quarters into the same reporting year — through August 12 — it was down 5.4% worldwide, on the Top 100’s first Q3 over $6B (Pollstar).

A record first-half total built on 18.2% more shows tells you the calendar got busier. It does not tell you the date in front of you got stronger — and the date is the only thing you’re underwriting.